Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Accumulated Depreciation (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Accumulated Depreciation for 9 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 18.19% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2025, up 18.19% year-over-year, with the annual reading at $8.3 million for FY2025, 18.19% up from the prior year.
  • Accumulated Depreciation hit $8.3 million in Q4 2025 for Protagonist Therapeutics, up from $7.9 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $8.3 million in Q4 2025 to a low of $4.3 million in Q4 2021.
  • Historically, Accumulated Depreciation has averaged $6.2 million across 5 years, with a median of $6.2 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation: increased 23.39% in 2022 and later rose 12.43% in 2025.
  • Year by year, Accumulated Depreciation stood at $4.3 million in 2021, then grew by 23.39% to $5.3 million in 2022, then grew by 18.65% to $6.2 million in 2023, then increased by 12.85% to $7.0 million in 2024, then grew by 18.19% to $8.3 million in 2025.
  • Business Quant data shows Accumulated Depreciation for PTGX at $8.3 million in Q4 2025, $7.9 million in Q3 2025, and $7.6 million in Q2 2025.